Abiomed Inc chart

Last update: 2022-12-23
Key statistics and financials
Revenue per share 23.61
Dividend & YieldN/A$ (N/A)
Beta 1.28
Market capitalization 17.01B
Operating cash flow 250.98M
ESG Scores unknown

Company description

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Sector: Healthcare - Industry: Medical Devices

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities 9.48M 5.37M 7.8M 2.96M
Total Cashflows From Investing Activities -116.45M -125.45M -223.34M -380.99M
Net Borrowings
Total Cash From Financing Activities -55.77M -117.72M -8.07M -2.2M
Change To Operating Activities 10.88M 10.34M -15.66M -9.17M
Issuance Of Stock 16M 8.85M 14.55M 16.66M
Net Income 259.02M 203.01M 225.53M 136.5M
Change In Cash 78.05M 71.32M 40.37M -99.89M
Effect Of Exchange Rate -1.92M -430k -2.8M -2.09M
Total Cash From Operating Activities 252.2M 314.92M 274.58M 285.39M
Depreciation 14.12M 20.43M 23.35M 28.09M
Change To Account Receivables -22.02M 5.55M -12.06M 5.33M
Other Cashflows From Financing Activities -2.33M -2.33M -2.33M -2.33M
Change To Netincome 17.9M 83.46M 42.34M 150.99M
Capital Expenditures -44M -44.01M -53.38M -35.76M

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development 94.42M 99.33M 119.47M 163.4M
Income Before Tax 263.36M 256.82M 288.22M 190.56M
Net Income 259.02M 203.01M 225.53M 136.5M
Selling General Administrative 321.55M 341.6M 333.28M 423.49M
Gross Profit 639.87M 689.58M 685.62M 843.6M
Ebit 223.9M 248.64M 232.86M 256.71M
Operating Income 223.9M 248.64M 232.86M 256.71M
Interest Expense
Income Tax Expense 4.34M 53.82M 62.7M 54.05M
Total Revenue 769.43M 840.88M 847.52M 1.03B
Cost Of Revenue 129.57M 151.31M 161.91M 188.16M
Total Other Income ExpenseNet 39.46M 8.18M 55.36M -66.15M
Net Income From Continuing Ops 259.02M 203.01M 225.53M 136.5M
Net Income Applicable To Common Shares 259.02M 203.01M 225.53M 136.5M

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 117.46M 151M 164.68M 170.07M
Total Stockholder Equity 936.89M 1.07B 1.33B 1.5B
Other Current Liabilities 17.66M 22.15M 27.68M 26.36M
Total Assets 1.05B 1.22B 1.49B 1.67B
Common Stock 451k 451k 453k 455k
Other Current Assets
Retained Earnings 399.47M 602.48M 828.01M 964.51M
Treasury Stock -153.54M -276.6M -299.48M -331.71M
Cash 121.02M 192.34M 232.71M 132.82M
Total Current Liabilities 106M 131.88M 128.97M 138.46M
Other Stockholder Equity -14.69M -11.19M -11.45M -27.16M
Property, Plant, and Equipment 145M 176.69M 203.24M 202.49M
Total Current Assets 677.2M 635.86M 787.97M 976.47M
Net Tangible Assets 899.95M 1.03B 1.22B 1.39B
Net Receivables 90.81M 84.65M 97.18M 90.61M
Accounts Payable 32.19M 32.77M 34.84M 35.35M


Insider Transactions

Here are the insider transactions of stock shares related to Abiomed Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
SUTTER MARTIN PSale at price 374.18 - 375.56 per share.D2022-11-16Director4k
BEGAN MARC A.Sale at price 373.71 per share.D2022-11-04General Counsel2k
THOMAS PAUL GSale at price 379.38 per share.D2022-11-01Director1k
TRAPP TODD ASale at price 377.82 - 380.20 per share.D2022-11-01Chief Financial Officer1k
PLANO MATTHEW TSale at price 377.84 - 380.22 per share.D2022-11-01Officer3.54k
PLANO MATTHEW TConversion of Exercise of derivative security at price 223.90 per share.D2022-11-01Officer1.84k
MINOGUE MICHAEL RStock Award(Grant) at price 0.00 per share.D2022-09-30Chief Executive Officer32
GREENFIELD ANDREW JStock Award(Grant) at price 0.00 per share.D2022-09-30Officer34
BEGAN MARC A.Sale at price 255.95 per share.D2022-08-29General Counsel500
SUTTER MARTIN PSale at price 280.59 - 293.44 per share.D2022-08-17Director4k
RIVET JEANNINE M.Stock Award(Grant) at price 0.00 per share.D2022-08-10Director681
ROSE ERIC AStock Award(Grant) at price 0.00 per share.D2022-08-10Director681
SUTTER MARTIN PStock Award(Grant) at price 0.00 per share.D2022-08-10Director681
THOMAS PAUL GStock Award(Grant) at price 0.00 per share.D2022-08-10Director681
PUHY DOROTHY EStock Award(Grant) at price 0.00 per share.D2022-08-10Director681
JOHNSON PAULA AStock Award(Grant) at price 0.00 per share.D2022-08-10Director681
VAN GORDER CHRISTOPHER D.Stock Award(Grant) at price 0.00 per share.D2022-08-10Director681
ROLLE MYRON LStock Award(Grant) at price 0.00 per share.D2022-08-10Director681
TRAPP TODD ASale at price 300.00 per share.D2022-08-03Chief Financial Officer1k
MINOGUE MICHAEL RStock Award(Grant) at price 0.00 per share.D2022-05-27Chief Executive Officer30.2k
GREENFIELD ANDREW JStock Award(Grant) at price 0.00 per share.D2022-05-27Officer7.5k
TRAPP TODD AStock Award(Grant) at price 0.00 per share.D2022-05-27Chief Financial Officer6.83k
BEGAN MARC A.Stock Award(Grant) at price 0.00 per share.D2022-05-27General Counsel6.88k
PLANO MATTHEW TStock Award(Grant) at price 0.00 per share.D2022-05-27Officer3.95k
SUTTER MARTIN PSale at price 240.07 - 262.18 per share.D2022-05-18Director4k
TRAPP TODD ASale at price 333.00 per share.D2022-04-04Chief Financial Officer1k
MINOGUE MICHAEL RStock Award(Grant) at price 0.00 per share.D2022-03-31Chief Executive Officer43
GREENFIELD ANDREW JStock Award(Grant) at price 0.00 per share.D2022-03-31Officer25
WEBER DAVID MSale at price 340.00 per share.D2022-03-31Chief Operating Officer7.5k
SUTTER MARTIN PSale at price 307.64 - 321.61 per share.D2022-02-17Director4k
SUTTER MARTIN PSale at price 295.55 - 324.33 per share.D2022-02-16Director2k
WEBER DAVID MSale at price 325.00 per share.D2022-02-16Chief Operating Officer7.5k
SUTTER MARTIN PSale at price 296.18 - 306.68 per share.D2022-02-15Director2k
WEBER DAVID MSale at price 300.25 - 310.19 per share.D2022-02-09Chief Operating Officer10.82k
WEBER DAVID MConversion of Exercise of derivative security at price 21.55 per share.D2022-02-09Chief Operating Officer10.82k
TRAPP TODD ASale at price 359.43 per share.D2022-01-05Chief Financial Officer1k
SUTTER MARTIN PSale at price 336.06 - 354.59 per share.D2021-11-18Director22.5k
MINOGUE MICHAEL RStock Award(Grant) at price 0.00 per share.D2021-11-03Chief Executive Officer23.25k
GREENFIELD ANDREW JStock Award(Grant) at price 0.00 per share.D2021-11-03Officer6.97k
WEBER DAVID MStock Award(Grant) at price 0.00 per share.D2021-11-03Chief Operating Officer6.97k
TRAPP TODD AStock Award(Grant) at price 0.00 per share.D2021-11-03Chief Financial Officer6.97k
BEGAN MARC A.Stock Award(Grant) at price 0.00 per share.D2021-11-03General Counsel6.97k
MINOGUE MICHAEL RStock Award(Grant) at price 0.00 per share.D2021-09-30Chief Executive Officer36
GREENFIELD ANDREW JStock Award(Grant) at price 0.00 per share.D2021-09-30Officer26
MINOGUE MICHAEL RSale at price 350.00 per share.D2021-08-23Chief Executive Officer3.49k
MINOGUE MICHAEL RConversion of Exercise of derivative security at price 23.15 per share.D2021-08-23Chief Executive Officer3.49k
SUTTER MARTIN PStock Gift at price 0.00 per share.D2021-08-19Director1k
SUTTER MARTIN PSale at price 323.19 - 335.64 per share.D2021-08-18Director7.5k
THOMAS PAUL GSale at price 330.77 per share.D2021-08-18Director663
RIVET JEANNINE M.Stock Award(Grant) at price 0.00 per share.D2021-08-11Director625
ROSE ERIC AStock Award(Grant) at price 0.00 per share.D2021-08-11Director625

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Abiomed Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Abiomed Inc

Here is the result of two systematic investment strategies applied to Abiomed Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Abiomed Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Abiomed Inc:

Abiomed Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 30.49% on the backtest period.

Performance at glance

Performance

30.49 %

Latent gain

591.57 $

Invested capital

1940.4 $

Annualized return

7.44 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Abiomed Inc

This is the result of two momentum investment strategies applied to Abiomed Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Abiomed Inc

The following chart shows all the entries opened by the momentum investment system on Abiomed Inc:

Abiomed Inc momentum entries
  • The first momentum investment strategy would give 34.64% of return on Abiomed Inc. That represents 1767.96$ of latent gain with 5104.53$ of employed capital.
  • The second momentum investment strategy would give 25.62% of return on Abiomed Inc. That represents 1253.99$ of latent gain with 4895.08$ of employed capital.
Performance at glance (1Q Momentum)

Performance

34.64 %

Latent gain

1767.96 $

Invested capital

5104.53 $

Annualized return

50.25 %
Performance at glance (2Q Momentum)

Performance

25.62 %

Latent gain

1253.99 $

Invested capital

4895.08 $

Annualized return

7.08 %

Momentum equity curve on Abiomed Inc

The following chart shows the equity curve of the two momentum strategies applied to Abiomed Inc:

Abiomed Inc momentum equity

Note: the dividends potentially given by Abiomed Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Abiomed Inc

The following chart shows the employed capital evolution of the two momentum strategies on Abiomed Inc since the beginning:

Abiomed Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Abiomed Inc

Buy the dip entry openings on Abiomed Inc

Abiomed Inc

The performance achieved by the robo-advisor on Abiomed Inc is 105.53%. That represents 742.88$ of latent gain with 703.96$ of employed capital. The following chart shows Abiomed Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Abiomed Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

105.53 %

Latent gain

742.88 $

Invested capital

703.96 $

Annualized return

50.25 %

Equity curve of the strategy applied to Abiomed Inc

The following chart shows the result of the investment strategy applied to Abiomed Inc:

Abiomed Inc

Note: the dividends potentially given by Abiomed Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Abiomed Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Abiomed Inc:

Abiomed Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Abiomed Inc

In this section, I will compare the three previous investment strategies applied to Abiomed Inc.

Equity curve comparison on Abiomed Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Abiomed Inc investment strategy comparison

Employed capital comparison on Abiomed Inc

Abiomed Inc investment comparison

Performance comparison on Abiomed Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 30.49% 591.57$ 1940.4$ 7.44%
Momentum 1 quarter 34.64% 1767.96$ 5104.53$ 8.97%
Momentum 2 quarters 25.62% 1253.99$ 4895.08$ 7.08%
Non-directional 105.53% 742.88$ 703.96$ 50.25%
Annualized return comparison

Automatic investment

7.44 %

Momentum 1Q

7.08 %

Momentum 2Q

7.08 %

Non-directional

50.25 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Abiomed Inc:

Note: The algorithm computes the probability of correlation between Abiomed Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Abiomed Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Abiomed Inc
Country United States
City Danvers
Address 22 Cherry Hill Drive
Phone 978 646 1400
Website www.abiomed.com
FullTime employees 2003
Industry Medical Devices
Sector Healthcare
Exchange XNAS
Ticker ABMD
Market www.nasdaq.com

Abiomed Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown